A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Bleselumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
    • 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top